The BioNTech laboratory takes a dose of artificial intelligence

Spread the love

The German biotech has just put 400 million euros on the table to swallow InstaDeep.

The BioNTech laboratory takes a dose of artificial intelligence

BioNTech cannot afford to waste time against a Moderna in growing, ready to deploy its knowledge in new treatments, from the flu to skin cancer. The German laboratory has just acquired 100% of the shares of the startup InstaDeep, rich in the artificial intelligence it is developing.

“240 highly qualified professionals” will join biotech teams, with the means to push further and more quickly the “large-scale development of next-generation immunotherapies”.

InstaDeep launched in Tunisia before moving to London, where it already received $100 million in funding last year, much of it from BioNTech.

Learning automation and artificial intelligence will keep pace with “the rapid evolution of the digital world in our technologies, our research, our drug discovery, manufacturing and deployment processes”, explained Professor Ugur at the time. Sahin, MD, CEO and co-founder of BioNTech. He added that his “goal is to make BioNTech a technology company where AI is seamlessly integrated into all aspects of our work”.

$13.4 billion 8217; euros in cash

Like Moderna, BioNTech has enriched itself enormously from the coronavirus pandemic by commercializing its mRNA vaccine in many countries. In its treasury, at the end of last year, it had no less than 13.4 billion euros, recalled Le Figaro.For 2023, one of its main objectives is to strengthen its capacities in Asia-Pacific.

To do this, the biotech invested in a new production plant in Singapore in November, acquired from Novartis. The key word here again, go faster, always faster. “faster capacity for potential clinical trials and commercial delivery of our vaccines”, commented Sierk Poetting, COO of BioNTech.

At the competition , Moderna recently took more than 20% on the stock market after the announcement of a promising development of a new treatment for skin cancer.

At Pfizer, it is also time for research on solutions for several forms of cancer and the company was spending no less than 6 billion euros at the end of 2021 to buy one of its competitors, called Arena Pharmaceuticals. The American group, which specializes in cardiology and gastroenterology in particular, will allow Pfizer to expand into other pathologies.

Previous Article
Next Article